{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:10:02Z","timestamp":1758964202376,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.clinthera.2020.05.007","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T17:43:07Z","timestamp":1593020587000},"page":"1292-1301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis"],"prefix":"10.1016","volume":"42","author":[{"given":"M.Q.","family":"Deslandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.T.","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Alvarenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.C.C.","family":"Lessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.P.","family":"Alvarenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0833-4024","authenticated-orcid":false,"given":"Claudia C.","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.05.007_bib1","article-title":"Brain health: time matters in multiple sclerosis","author":"Giovannoni","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clinthera.2020.05.007_bib2","doi-asserted-by":"crossref","DOI":"10.1586\/ern.11.15","article-title":"Principles of a new treatment algorithm in multiple sclerosis","author":"Hartung","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2020.05.007_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000361044","article-title":"Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study","volume":"72","author":"Gajofatto","year":"2014","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-010-0344-z","article-title":"Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study","volume":"31","author":"Sangalli","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clinthera.2020.05.007_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa044397","article-title":"A\u00a0randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","author":"Polman","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.007_bib6","article-title":"A\u00a0randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","author":"Panzara","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.007_bib7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.007_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","article-title":"Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study","volume":"16","author":"Oturai","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2011.45","article-title":"Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data","author":"Cree","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib11","article-title":"Clinical effects of natalizumab on multiple sclerosis appear early in treatment course","author":"Kappos","year":"2013","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.33588\/rn.5909.2013479","article-title":"Portugal Experience with Natalizumab Study Group. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study","volume":"59","author":"Sousa","year":"2014","journal-title":"Rev Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223863","article-title":"The effectiveness of interferon-beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population","volume":"14","author":"Kapica-Topczewska","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.05.007_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12883-019-1337-z","article-title":"Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE","volume":"19","author":"Perumal","year":"2019","journal-title":"BMC Neurol"},{"issue":"11","key":"10.1016\/j.clinthera.2020.05.007_bib15","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.33588\/rn.3511.2002381","article-title":"Cl\u00ednica de la esclerosis m\u00faltiple recidivante-remitente. Factores pron\u00f3sticos","volume":"35","author":"Fern\u00e1ndez-Fern\u00e1ndez","year":"2002","journal-title":"Rev Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1468-1331.2008.02519.x","article-title":"Natalizumab is effective as second-line therapy in the treatment of relapsing-remitting multiple sclerosis","volume":"16","author":"Putzki","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib17","doi-asserted-by":"crossref","DOI":"10.1590\/0004-282X20150098","article-title":"Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers","author":"Oliveira","year":"2015","journal-title":"Arq Neuropsiquiatr"},{"issue":"6","key":"10.1016\/j.clinthera.2020.05.007_bib18","first-page":"321","article-title":"An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis","volume":"52","author":"Horga","year":"2011","journal-title":"Rev Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib19","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2020.05.007_bib20","doi-asserted-by":"crossref","DOI":"10.1159\/000375371","article-title":"Effectiveness of natalizumab in patients with highly active relapsing-remitting multiple sclerosis","author":"Cobo-Calvo","year":"2015","journal-title":"Eur Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2016.03.025","article-title":"Long-term assessment of no evidence of disease activity with natalizumab in relapsing multiple sclerosis","author":"Prosperini","year":"2016","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.clinthera.2020.05.007_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ncl.2004.10.002","article-title":"Natural history of multiple sclerosis","volume":"23","author":"Kantarci","year":"2005","journal-title":"Neurol Clin"},{"key":"10.1016\/j.clinthera.2020.05.007_bib23","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","author":"Trapp","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.05.007_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.msard.2018.04.020","article-title":"Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting","volume":"24","author":"Trojano","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clinthera.2020.05.007_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.03112.x","article-title":"Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis","author":"Belachew","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/039463201402700201","article-title":"Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy","author":"Totaro","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib27","article-title":"Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis","author":"Casanova","year":"2011","journal-title":"Farm Hosp"},{"key":"10.1016\/j.clinthera.2020.05.007_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/WNF.0b013e31824644e6","article-title":"Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline","volume":"35","author":"Kallweit","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/1352458512460605","article-title":"Scoring treatment response in patients with relapsing multiple sclerosis","author":"Sormani","year":"2013","journal-title":"Mult Scler J"},{"key":"10.1016\/j.clinthera.2020.05.007_bib30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomized double-blind placebo-controlled study of interferon-beta 1a in relapsing\/remitting multiple sclerosis. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group","volume":"352","year":"1998","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2020.05.007_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/WCO.0b013e32812583ad","article-title":"Natural history of multiple sclerosis: risk factors and prognostic indicators","author":"Vukusic","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib32","article-title":"Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis","author":"Melin","year":"2012","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.clinthera.2020.05.007_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/1352458509360987","article-title":"Differences in the progression of primary progressive multiple sclerosis in Brazilians of African descent versus white Brazilian patients","author":"Ferreira Vasconcelos","year":"2010","journal-title":"Mult Scler"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820302411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:50Z","timestamp":1758963170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820302411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0149291820302411"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}